Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Risperdal risperidone: Phase III; marketed to treat schizophrenia

In a double-blind U.S. Phase III trial in 156 patients hospitalized for mania, patients treated

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE